These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 36405617)

  • 1. Do statins benefit low-risk population for primary prevention of atherosclerotic cardiovascular disease: A retrospective cohort study.
    Ryou IS; Kim JY; Park HY; Oh S; Kim S; Kim HJ
    Front Med (Lausanne); 2022; 9():1024780. PubMed ID: 36405617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.
    Zhan S; Tang M; Liu F; Xia P; Shu M; Wu X
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012502. PubMed ID: 30480766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of statins for the primary prevention of cardiovascular disease in the Asian elderly population.
    Lin YW; Wang CC; Wu CC; Hsu YT; Lin FJ
    Int J Cardiol; 2023 Feb; 373():25-32. PubMed ID: 36435332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
    Rosenblit PD
    Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid lowering therapy in patients with atherosclerotic cardiovascular diseases: Which matters in the real world? Statin intensity or low-density lipoprotein cholesterol level? ‒ Data from a multicenter registry cohort study in Taiwan.
    Yeh YT; Yin WH; Tseng WK; Lin FJ; Yeh HI; Chen JW; Wu YW; Wu CC;
    PLoS One; 2017; 12(10):e0186861. PubMed ID: 29073192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative contributions of statin intensity, achieved low-density lipoprotein cholesterol level, and statin therapy duration to cardiovascular risk reduction in patients with type 2 diabetes: population based cohort study.
    Kim JY; Choi J; Kim SG; Kim NH
    Cardiovasc Diabetol; 2022 Feb; 21(1):28. PubMed ID: 35193571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study.
    Ramos R; Comas-Cufí M; Martí-Lluch R; Balló E; Ponjoan A; Alves-Cabratosa L; Blanch J; Marrugat J; Elosua R; Grau M; Elosua-Bayes M; García-Ortiz L; Garcia-Gil M
    BMJ; 2018 Sep; 362():k3359. PubMed ID: 30185425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does Lowering Low-Density Lipoprotein Cholesterol With Statin Restore Low Risk in Middle-Aged Adults? Analysis of the Observational MESA Study.
    Liu K; Wilkins JT; Colangelo LA; Lloyd-Jones DM
    J Am Heart Assoc; 2021 Jun; 10(11):e019695. PubMed ID: 33998284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensity of statin therapy, achieved low-density lipoprotein cholesterol levels and cardiovascular outcomes in Japanese patients after coronary revascularization. Perspectives from the CREDO-Kyoto registry cohort-2.
    Natsuaki M; Furukawa Y; Morimoto T; Nakagawa Y; Ono K; Kaburagi S; Inada T; Mitsuoka H; Taniguchi R; Nakano A; Kita T; Sakata R; Kimura T;
    Circ J; 2012; 76(6):1369-79. PubMed ID: 22447012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statin therapy and cardiovascular protection in type 2 diabetes: The role of baseline LDL-Cholesterol levels. A systematic review and meta-analysis of observational studies.
    Soroush N; Nekouei Shahraki M; Mohammadi Jouabadi S; Amiri M; Aribas E; Stricker BH; Ahmadizar F
    Nutr Metab Cardiovasc Dis; 2024 Apr; ():. PubMed ID: 38866619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polygenic Risk Score and Statin Relative Risk Reduction for Primary Prevention of Myocardial Infarction in a Real-World Population.
    Oni-Orisan A; Haldar T; Cayabyab MAS; Ranatunga DK; Hoffmann TJ; Iribarren C; Krauss RM; Risch N
    Clin Pharmacol Ther; 2022 Nov; 112(5):1070-1078. PubMed ID: 35862449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statins, risk of diabetes, and implications on outcomes in the general population.
    Wang KL; Liu CJ; Chao TF; Huang CM; Wu CH; Chen SJ; Chen TJ; Lin SJ; Chiang CE
    J Am Coll Cardiol; 2012 Oct; 60(14):1231-8. PubMed ID: 22884288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of Nontraditional Risk Markers in Individuals Ineligible for Statin Therapy According to the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines.
    Yeboah J; Polonsky TS; Young R; McClelland RL; Delaney JC; Dawood F; Blaha MJ; Miedema MD; Sibley CT; Carr JJ; Burke GL; Goff DC; Psaty BM; Greenland P; Herrington DM
    Circulation; 2015 Sep; 132(10):916-22. PubMed ID: 26224808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The low-density lipoprotein cholesterol lowering is an ineffective surrogate marker of statin responsiveness to predict cardiovascular outcomes: The 10-year experience of matched population (a STROBE-compliant article).
    Hyun MH; Jang JW; Choi BG; Na JO; Choi CU; Kim JW; Kim EJ; Rha SW; Park CG; Lee E; Seo HS
    Medicine (Baltimore); 2019 Dec; 98(51):e18510. PubMed ID: 31861037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Long-term Benefit Approach vs Standard Risk-Based Approaches for Statin Eligibility in Primary Prevention.
    Thanassoulis G; Sniderman AD; Pencina MJ
    JAMA Cardiol; 2018 Nov; 3(11):1090-1095. PubMed ID: 30422172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of Statins as Secondary Prevention Against Recurrent and Terminal Major Adverse Cardiovascular Events.
    Tecson KM; Kluger AY; Cassidy-Bushrow AE; Liu B; Coleman CM; Jones LK; Jefferson CR; VanWormer JJ; McCullough PA
    Am J Cardiol; 2022 Aug; 176():37-42. PubMed ID: 35606173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of Incident Atherosclerotic Cardiovascular DiseaseEvents by Achieved Atherogenic Lipid Levels Among62,428 Statin-Treated Individuals With Diabetes Mellitus.
    Rana JS; Liu JY; Moffet HH; Boklage SH; Khan I; Karter AJ
    Am J Cardiol; 2018 Sep; 122(5):762-767. PubMed ID: 30057224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statin Intensity and Clinical Outcome in Patients with Stable Coronary Artery Disease and Very Low LDL-Cholesterol.
    Lee SY; Oh SJ; Kim EJ; Oum CY; Park SH; Oh J; Kim JS; Kim BK; Park S; Chang HJ; Hong GR; Ko YG; Kang SM; Choi D; Ha JW; Hong MK; Jang Y; Chung N; Lee SH
    PLoS One; 2016; 11(11):e0166246. PubMed ID: 27824924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-density lipoprotein cholesterol response after statin initiation among persons living with human immunodeficiency virus.
    Burkholder GA; Muntner P; Zhao H; Mugavero MJ; Overton ET; Kilgore M; Drozd DR; Crane HM; Moore RD; Mathews WC; Geng E; Boswell S; Floris-Moore M; Rosenson RS
    J Clin Lipidol; 2018; 12(4):988-998.e5. PubMed ID: 29853312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statins for Prevention of Cardiovascular Events in a Low-Risk Population With Low Ankle Brachial Index.
    Ramos R; García-Gil M; Comas-Cufí M; Quesada M; Marrugat J; Elosua R; Sala J; Grau M; Martí R; Ponjoan A; Alves-Cabratosa L; Blanch J; Bolíbar B
    J Am Coll Cardiol; 2016 Feb; 67(6):630-640. PubMed ID: 26868687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.